Revolutionary cell therapy tested for Tough-to-Treat lupus kidney damage
NCT ID NCT05938725
Summary
This early-stage study is testing a new therapy called KYV-101 for adults with severe lupus nephritis, a serious kidney disease caused by lupus, that hasn't improved with standard treatments. The therapy involves collecting a patient's own immune cells, modifying them in a lab to target and remove harmful B cells thought to drive the disease, and then infusing them back. The main goals are to check the treatment's safety, find the right dose, and see if it can help patients achieve a complete recovery of their kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwell Health
Great Neck, New York, 11021, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
-
University of Colorado
Denver, Colorado, 80045, United States
-
University of Massachusetts Worcester
Worcester, Massachusetts, 01655, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.